Risk factors and impact of Clostridium difficile recurrence on haematology patients

The incidence of Clostridium difficile infection (CDI) in adults with malignancy is 7%-14% compared with 1%-2% in the general hospitalized population. Despite the increased incidence of CDI in this population, a major concern is the propensity of CDI to recur, leading to delays in therapy impacting...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2017-05, Vol.72 (5), p.1488-1495
Main Authors: Scappaticci, Gianni B, Perissinotti, Anthony J, Nagel, Jerod L, Bixby, Dale L, Marini, Bernard L
Format: Article
Language:English
Subjects:
Aged
Case-Control Studies
Clostridium difficile - isolation & purification
Clostridium Infections - complications
Clostridium Infections - epidemiology
Clostridium Infections - microbiology
Female
Hematologic Neoplasms - complications
Hematologic Neoplasms - drug therapy
Hematologic Neoplasms - epidemiology
Humans
Incidence
Logistic Models
Male
Middle Aged
Multivariate Analysis
Recurrence
Retrospective Studies
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The incidence of Clostridium difficile infection (CDI) in adults with malignancy is 7%-14% compared with 1%-2% in the general hospitalized population. Despite the increased incidence of CDI in this population, a major concern is the propensity of CDI to recur, leading to delays in therapy impacting outcomes. We conducted a retrospective case-control study to identify risk factors for recurrent CDI (rCDI) and to determine the impact of rCDI on adult patients with a haematological malignancy. Adult haematology patients with CDI from June 2010 to December 2014 were divided into two groups: rCDI and non-rCDI. Multivariable models using logistic regression were constructed to identify risk factors for rCDI. A total of 100 patients in our study yielded a 41% recurrence rate. CDI impacted chemotherapy significantly more in the rCDI group (53.7% versus 11.9%, P  
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkx005